References
Agnelli G (1997) Venous thromboembolism and cancer: a two way clinical association. Thromb Haemost 78:117–120
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907
Barni S, La Bianca R, Agnelli G, Bonizzoni E, Verso M, Mandalà M, Brighenti M, Petrelli F, Bianchini C, Perrone T, Gasparini G (2011) Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med 9:179–185
Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E (2009) For the PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in outpatients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10:943–949
Streiff MB, Bockenstedt PL, Cataland PR, Chesney C, Eby C, Fanikos J, Fogarty PF, Gao S, Garcia-Aguilar J, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Jones KA, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Smith JL, Yee GC, Zakarija A (2011) Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 9:714–775
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
For the Protecht investigators.
Rights and permissions
About this article
Cite this article
Verso, M., Agnelli, G., Barni, S. et al. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7, 291–292 (2012). https://doi.org/10.1007/s11739-012-0784-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-012-0784-y